Shares of Renalytix Plc (NASDAQ:RNLX – Get Free Report) were up 5.7% on Wednesday . The company traded as high as $0.23 and last traded at $0.21. Approximately 934,400 shares changed hands during trading, a decline of 36% from the average daily volume of 1,451,440 shares. The stock had previously closed at $0.20.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Renalytix in a research note on Friday, July 12th.
Get Our Latest Research Report on Renalytix
Renalytix Stock Performance
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Renalytix stock. Levin Capital Strategies L.P. purchased a new position in Renalytix Plc (NASDAQ:RNLX – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 555,000 shares of the company’s stock, valued at approximately $128,000. Levin Capital Strategies L.P. owned about 0.72% of Renalytix at the end of the most recent quarter. Institutional investors own 9.92% of the company’s stock.
Renalytix Company Profile
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.
Read More
- Five stocks we like better than Renalytix
- NYSE Stocks Give Investors a Variety of Quality Options
- Survey Reveals: America’s Most Coveted Businesses in 2024
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- What is a Death Cross in Stocks?
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.